Agios Pharmaceuticals, Inc.

“Agios is committed to supporting patients and their families seeking to explore all available treatment options. Individuals currently diagnosed with Pyruvate kinase (PK) deficiency who are unable to access treatment may be eligible for treatment through our Global Managed Access Program when certain criteria are met.”

“Our Global Managed Access Program (GMAP) offers a pathway for patients to obtain access to PYRUKYND® (mitapivat) provided they meet the defined criteria and reside in a country where access is permissible under local laws and regulations.”

Agios is committed to providing access to treatments that make a meaningful difference in patients’ lives. Part of this commitment is the Agios Global Managed Access Program (GMAP), which provides a pathway for adults in the European Union diagnosed with PK deficiency to have access to our approved medicine. Healthcare providers may submit an inquiry on behalf of their patients to Agios for consideration. (Healthcare providers outside the U.S. only)

In addition, we have a Global Managed Access Program (GMAP) aimed at providing access to PYRUKYND® in regions where the drug is not yet widely available. The GMAP was recently launched in the European Union and Great Britain after the approval of PYRUKYND® in these regions, and EU and Great Britain healthcare providers may submit an inquiry on behalf of their patients.

To authenticate you as a user, communicate with you and investigate and respond to your inquiries, including those inquiries for expanded access. At your request, we may use information you provide in your communications to contact you with information regarding Research, evaluate your eligibility for the Research and, as appropriate, to invite you to participate in Research.